Wednesday, May 8, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Russian Pharmaceutical Forum in Saint Petersburg, May 15.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for drug discovery, conducting clinical trials, personalised medicine, and rare disease identification.
"We are happy to present our latest research at the Russian Pharmaceutical Forum, which gathers the leading industry leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Aliper, President of EMEA at Insilico Medicine.
The Russian Pharmaceutical Forum remains the largest independent international conference in Russia devoted to addressing the pharmaceutical industry's most pressing issues. The key topics the Forum aims to approach, include: digitalisation in healthcare and pharmaceutical sector, pharmaceutical drug reimbursement, drug labeling, the patient-centric model, state purchasing, import substitution, innovation potential.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
Website: http://insilico.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Website: http://insilico.
No comments:
Post a Comment